Advertisement
Articles
Subscribe to Drug Discovery & Development Articles

The Lead

The Future of Genome Analysis

August 28, 2014 | by Maxim Mikheev, M.D., Ph.D., Co-Founder and Chief Technical Officer at BioDatomics | Comments

As technological improvements have changed the way we study the genome, the amount of data associated with a single DNA sample has increased exponentially. Surprisingly, throughout this evolution the hardware and software infrastructure supporting bioanalytics has barely changed. Read more...

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Accelerate Drug Development with Optimized Content Management

August 29, 2014 8:30 am | by Steve Scribner, Principal Consultant – Life Sciences, EMC Information Intelligence Group | Comments

Getting a new drug from the laboratory to the pharmacy takes years of testing, applications and information sharing. One way to shorten the drug development life cycle is to optimize content management. Read more...          

TOPICS:

A ‘Second Revolution’ in Drug Discovery and Development

August 27, 2014 9:58 am | by Seth Lederman, M.D., CEO, Tonix Pharmaceuticals | Comments

Drugs can be discovered and developed in two very different ways: at an evolutionary pace and at a revolutionary pace. The “first revolution” in biological psychiatry took place in the 1950s, and now, in the 21st century, a “second revolution” of drug development and discovery is taking place, driven by repurposing. Read more...

TOPICS:

Drug Cured 16 of 16 Monkeys with Viral Ebola Relative

August 26, 2014 11:31 am | by Cynthia Fox, Science Editor | Comments

An experimental drug saved the lives of 16 of 16 monkeys with the Marburg virus, a killer near-indistinguishable from Ebola, just as symptoms broke out, said a new study. Read more...                   

TOPICS:
Advertisement

‘The Pill’ Shrinks Ovaries, Cuts Egg Numbers

August 25, 2014 9:49 am | by Cynthia Fox, Science Editor | Comments

The birth control pill significantly affects ovarian reserve— or the number of immature eggs in a woman’s ovaries— which can be a predictor of future fertility, according to a team in Denmark. Read more...             

TOPICS:

The Case for Orphan Drugs

August 22, 2014 10:34 am | by Louise Rozik, Editor | Comments

Neglected by the pharmaceutical industry before the Orphan Drug Act of 1983, rare diseases are now front and center in pharma R&D, with approximately one-third of all new medicines approved by the FDA in the past 5 years having been developed for the treatment of diseases that affect fewer than 200,000 Americans. Read more...

TOPICS:

Amid ALS Mania, Possible Drug Target Spotted

August 21, 2014 3:02 pm | by Cynthia Fox, Science Editor | Comments

As, all around them, everyone from Derek Jeter to the Kennedy family was dousing themselves in ice water for the ALS “Ice Bucket Challenge,” Harvard researchers announced last week they may have found an ALS therapy. Read more...      

TOPICS:

Rating U.S. Drug Development Programs

August 20, 2014 11:10 am | by Chris Plaford, CFA, Chief Executive Officer, Claravant Analytics LLC | Comments

According to industry estimates, the majority of drugs in development will never make it to FDA approval. While a lack of efficacy is often a key factor, many clinical programs are derailed due to avoidable setbacks that can cause delays and significantly increase costs. Read more...

TOPICS:

Small Molecules, Stem Cells Can Improve Hearing

August 18, 2014 3:14 pm | by Cynthia Fox, Science Editor | Comments

A scientist has found that a compound, LY-411575, can restore 20% of hearing in deaf mice, or ten decibels. Since electroacoustic hearing aids, at best, improve hearing by five decibels, there is a “good chance” the work will lead to help for deafened patients.

TOPICS:
Advertisement

Developing Multi-Functional Anti-Inflammatory Drugs

July 24, 2014 10:44 am | by Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics | Comments

Recent years have witnessed the development of novel, non-steroidal anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs) focusing has been on one of the most sought-after pharmaceutical targets in inflammation research: the secretory phospholipase A2 family. Read more...

TOPICS:

Reoviruses: The Discovery of Their Potential in Cancer Therapeutics

July 17, 2014 10:23 am | by Brad Thompson, Ph.D., President and Chief Executive Officer of Oncolytics Biotech | Comments

Reoviruses - first isolated in 1951 - are benign viruses with an important property: they are oncolytic, meaning they are capable of infecting and destroying many kinds of cancer cells. The story of how this discovery was made is an exciting one. Read more...

TOPICS:

Centralized Data Management Improves Collaboration

July 15, 2014 11:16 am | by Dr. Paul Denny-Gouldson, VP of Strategic Solutions at IDBS | Comments

Inventiva, a recent spin-off from Abbott, is a French biotech company specializing in running and managing integrated drug discovery partnerships from target validation up to clinical candidate selection who realized that it would benefit from having a more integrated data processing system across its multiple laboratories. Read more...

TOPICS:

Addressing Side Effects of Mainstream Treatments

July 11, 2014 10:52 am | by Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus Therapeutics Inc. | Comments

The highest-profile symptoms of major diseases are well publicized, yet for many, the side effects of mainstream therapies for these diseases can also impact physical and psychological well-being. Luckily, advances in drug delivery have offered novel treatments. Read more...

TOPICS:

Some 500 Genes Differ in Bipolar Patients’ Neurons

July 2, 2014 3:16 pm | by Cynthia Fox, Science Editor | Comments

Neurons of patients with bipolar disorder (BP) differ from the norm in a “striking” 500 or so genes, according to preliminary data generated using the Nobel-Prize-winning iPSC (induced pluripotent stem cell) approach, by Salk Institute neuroscientist Fred Gage. Read more...

TOPICS:

Innovation Reins in Runaway Pharma Spending

July 1, 2014 1:21 pm | by Nancy Dreyfus, Contributing Science Writer | Comments

To combat the rising costs of bringing a new drug to market, pharmaceutical companies have taken a variety of innovative approaches, according to the U.K. Office of Health Economics, such as deciding earlier in the R&D process to discontinue drugs lacking strong market prospects and better controlling clinical costs. Read more...

TOPICS:

Keeping the Lid on R&D Costs

June 23, 2014 11:14 am | by Nancy Dreyfus, Contributing Science Writer | Comments

In the past, pharmaceutical companies bolstered profits with billion-dollar blockbuster drugs that treated large populations for common conditions, but with patents running out, and development costs soaring, that business model may no longer be sustainable. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading